化学
即时
核医学
放射化学
医学物理学
医学
食品科学
作者
Yan Wang,Chao Wang,Minzhou Huang,Songbing Qin,Jun Zhao,Shibiao Sang,Meng Zheng,Yicong Bian,Chenrong Huang,Hua Zhang,Lingchuan Guo,Jiwei Jiang,Chun Xu,Na Dai,Yushuang Zheng,Jiajun Han,Min Yang,Tao Xu,Liyan Miao
标识
DOI:10.1007/s00259-022-05903-9
摘要
Abstract Purpose Positron emission tomography (PET) with specific diagnostic probes for quantifying CD8+ T cells has emerged as a powerful technique for monitoring immune response. However, currently, most CD8+ T cell radiotracers are based on antibodies or antibody fragments, which are slowly cleared from circulation. Herein, we aimed to develop and assess 68Ga-NODAGA-SNA006 for instant PET (iPET) imaging of CD8+ T cells.Methods A novel nanobody without a hexahistidine (His6) tag, SNA006-GSC, was designed and site-specific conjugated with NODAGA-maleimide and radiolabeled with 68Ga. The PET imaging profiles of 68Ga-NODAGA-SNA006 were evaluated in BALB/c MC38-CD8+/CD8- tumor models and cynomolgus monkeys. Three lung cancer volunteers underwent whole-body PET/CT imaging after 68Ga-NODAGA-SNA006 administration. Biodistribution, pharmacokinetics and dosimetry of patients were also investigated. In addition, combined with immunohistochemistry (IHC), the quantitative performance of the tracer to monitor CD8 expression was evaluated in BALB/c MC38-CD8+/CD8- and human subjects.Results 68Ga-NODAGA-SNA006 was prepared with RCP>98% and SA>100 GBq/µmol. 68Ga-NODAGA-SNA006 exhibited specific tumor uptake in MC38-CD8+ tumors of xenografts, CD8-rich tissues (such as the spleen) of monkeys and CD8+ tumor lesions of patients within 1 h. Fast washout from circulation appeared in three volunteers (t1/2<20 min). A preliminary quantitative linear relationship (R2=0.9668, p<0.0001 for xenografts and R2= 0.7924, p=0.0013 for lung patients) appeared between 68Ga-NODAGA-SNA006 uptake and CD8 expression. 68Ga-NODAGA-SNA006 was well tolerated in all patients.Conclusion 68Ga-NODAGA-SNA006 PET imaging can instantly quantify CD8 expression with an ideal safety profile and is expected to be important for dynamically tracking CD8+ T cells and monitoring immune responses for individualized cancer immunotherapy.Trial Registration NCT05126927 (19 November 2021, retrospectively registered).
科研通智能强力驱动
Strongly Powered by AbleSci AI